Polish-British start-up Walletmor has confirmed the safety of its payment implant with further scientific research. The latest tests carried out by the renowned Konmex BioLabs laboratory confirmed that the implant does not exhibit cytotoxic properties and can be implanted e.g. in tissue under the skin of the palm. The tests were conducted in Poland in May this year in accordance with the world bio-compatibility standards ISO 10993-5:2009E (cytotoxicity) and 10993-12:2021E. Walletmor plans further ISO testing and international certification of its implant.
Polish-British startup Walletmor, whose creator is Wojciech Paprota from Lublin, has created the first globally acceptable payment implant. The device, which is installed in any part of the body under the skin, usually in the hand, can replace a bulky wallet and is a convenient alternative to a credit card or any other device with a payment function, including a smartphone. The implant is the size of a small safety pin and half a millimeter thick. It consists of a microprocessor and a silicon envelope acting as an antenna, which are enclosed in a hermetic bio-housing. And although the implant itself is not a so-called legal medical device, its creators have spent a total of nearly 10 years developing and subsequently confirming its safety for users.
The trust of our Clients all over the world is our absolute priority – says Wojciech Paprota, the creator of Walletmor implant. – Meticulous examinations carried out in accordance with ISO procedures by such a renowned testing company confirm that the implant can be placed safely and used for one’s own benefit and comfort”, adds the founder of Walletmor.
Most of the scientific, legislative and testing work has been done in the United States in the laboratory of VivoKey Technologies Inc. in Seattle. This is where a safe and non-adverse reaction polymer was born, which is, technically speaking, a so-called medical plastic for the production of medical devices. In parallel to the tests in the US, the Walletmor start-up has commissioned testing of the implant in Poland, in accordance with EU and international ISO standards. The aim of the tests commissioned in 2021 from Konmex BioLabs was to confirm whether the analysed product, when implanted, would not deviate from the standard and lead to adverse reactions such as cytotoxicity, i.e. whether the product, when in contact with living cells, would not destroy them.
